Lyell Immunopharma, Inc. Transfer to Investments
Lyell Immunopharma, Inc. (LYEL) reported Transfer to Investments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:TransferToInvestments · last filed 2023-02-28
- Lyell Immunopharma, Inc. transfer to investments for fiscal 2022 was $0.00.
- Lyell Immunopharma, Inc. transfer to investments for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Lyell Immunopharma, Inc. transfer to investments for fiscal 2020 was $6.00M.
- Lyell Immunopharma, Inc. transfer to investments for fiscal 2019 was $0.00.
| Period end | Transfer to Investments 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2020-12-31 | $6.00M 10-K · filed 2023-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |